Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis.

ABSTRACT:

Background

Janus kinase (JAK) inhibitors (JAKis) are effective therapeutic agents against rheumatoid arthritis (RA). However, patients having RA with particular risk factors may have a higher incidence of adverse effects (AEs), including major cardiovascular events (MACE) and infections. In this multicenter cohort study, we aimed to clarify the risk factors affecting the drug retention of JAKis in patients with RA.

Methods

We retrospectively evaluated patients with RA who received their first JAKi (tofacitinib, baricitinib, upadacitinib, or filgotinib) at our institute. The clinical outcomes, including AEs, were recorded, particularly MACE and serious infections. The drug retention rates were analyzed using the Kaplan-Meier method, and risk factors affecting drug retention r

SUBMITTER: Saito K 

PROVIDER: S-EPMC11239012 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature